Arcus Biosciences, Inc. (RCUS)
| Previous Close | 14.73 |
| Open | 14.73 |
| Bid | 15.00 x 1000 |
| Ask | 15.05 x 900 |
| Day's Range | 14.59 - 15.09 |
| 52 Week Range | 12.95 - 25.47 |
| Volume | |
| Avg. Volume | 826,203 |
| Market Cap | 1.363B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.15 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.20 |
- Business Wire
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
HAYWARD, Calif., April 24, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024. The selected abstracts presented in partnership with Gilead Sciences provide strong support for the companies’ portfolio of in
- Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
HAYWARD, Calif., April 23, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended March 31st, 2024.
- Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif., April 09, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 45,000 shares of the Company’s common stock at an exercise price per share of $16.97, which was the closing price on April 8, 2024, and restri
